Vasovagal syncope as a cause of syncope in long-QT syndrome.

Asians. It may suggest that PPR would be 1 of numerous risk factors of atherothrombosis and that the role of it may not explain the whole clinical events after percutaneous coronary intervention. Previous studies reported that high PPR is associated with poor clinical outcomes in patients with coronary artery disease (3,4). owever, it is not clear that tailored dosing or choice of antiplateet agents based on platelet function test can improve the prognosis f patients with high PPR. The GRAVITAS (Gauging Responiveness With A VerifyNow Assay–Impact on Thrombosis and afety) trial could not show the benefit of high-dose clopidogrel herapy in patients with high PPR (5). The TRIGGER-PCI Testing Platelet Reactivity in Patients Undergoing Elective Stent lacement on Clopidogrel to Guide Alternative Therapy With rasugrel) study was stopped early after an interim analysis evealed a primary event rate too low to allow for any meaningful omparison between clopidogrel and prasugrel (6). The results of major trials make us question whether PPR would be a odifiable factor of thrombosis or simply an intrinsic property eflecting one’s thrombotic status. Further studies are warranted to nvestigate these unsolved problems, especially regarding the ethic difference of response to antiplatelet regimen and the necessiies of personalized antiplatelet therapies.